Tacrine import alert
Executive Summary
FDA said it is reviewing the status of the alert, which began in December 1988. Sold as a "smart drug," Tacrine is being imported from unapproved sources in the Bahamas and Europe, the agency said. In a Sept. 24 "Talk Paper", FDA said that it has allowed "personal- use" importations of the drug "on a case-by-case basis." Importations have been allowed if assurances are given by a physician that the Alzheimer's patient "will be closely monitored to detect potential serious side effects." FDA prefers that "patients be encouraged to enroll in the Treatment IND".
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth